Oculis Q1 2024 Earnings Report

Oculis EPS Results

• Actual EPS: -$0.44
• Consensus EPS: -$0.41
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Oculis Revenue Results

• Actual Revenue: $0.22 million
• Expected Revenue: $0.28 million
• Beat/Miss: Missed by -$60.00 thousand
• YoY Revenue Growth: N/A

Oculis Announcement Details

• Quarter: Q1 2024
• Date: 5/8/2024
• Time: N/A
• Conference Call Date: Wednesday, May 8, 2024
• Conference Call Time: 6:00AM ET

Oculis (NASDAQ:OCS) AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for ophthalmic diseases. The company’s core expertise lies in novel drug‐delivery technologies designed to improve patient compliance by enabling topical treatment of conditions that traditionally require invasive injections. Oculis’s proprietary formulation platform aims to deliver small molecules and biologics effectively to both the anterior and posterior segments of the eye, addressing significant unmet needs in diseases such as diabetic macular edema, uveitis, glaucoma and optic neuropathies.

The most advanced program in Oculis’s pipeline is OCS-01, a topically administered formulation of dexamethasone for diabetic macular edema that is currently in Phase 2 clinical trials. Preliminary data have demonstrated promising reductions in retinal thickness and improvements in visual acuity, suggesting potential for a noninvasive alternative to intravitreal injections. Additional candidates under development include OCS-02, an anti‐inflammatory agent targeting anterior segment disorders, and OCS-05, a neuroprotection program aimed at optic nerve damage in glaucoma and ischemic optic neuropathy. These programs leverage the company’s optimized nanoparticle and micelle technologies to enhance corneal penetration and drug bioavailability.

Founded in 2014 and headquartered in Geneva, Switzerland, Oculis has established research collaborations and clinical trial sites across Europe and North America. The company operates a U.S. subsidiary to support regulatory activities with the U.S. Food and Drug Administration and to facilitate potential commercialization in the world’s largest ophthalmic market. Oculis also maintains partnerships with leading academic institutions and contract research organizations to advance its topical delivery platform and explore additional indications.

Oculis’s leadership team comprises industry veterans with extensive experience in ophthalmology, drug development and regulatory affairs. The board and executive management draw on decades of pharmaceutical and biotech expertise to guide clinical strategy and commercial planning. As the company progresses its pipeline toward pivotal studies, it remains focused on delivering transformative, noninvasive therapies that could reshape treatment paradigms for patients with vision-threatening diseases worldwide.